Brain metastases in metastatic cancer: a review of recent advances in systemic therapies
出版年份 2020 全文链接
标题
Brain metastases in metastatic cancer: a review of recent advances in systemic therapies
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume -, Issue -, Pages 1-15
出版商
Informa UK Limited
发表日期
2020-11-16
DOI
10.1080/14737140.2021.1851200
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
- (2020) Todd M. Bauer et al. Targeted Oncology
- Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases
- (2019) Elisabeth Sophie Bergen et al. CLINICAL CANCER RESEARCH
- Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
- (2019) Lucio Crinò et al. LUNG CANCER
- Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
- (2019) Lizza E.L. Hendriks et al. Journal of Thoracic Oncology
- Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non–small-cell Lung Carcinoma and Brain Metastases
- (2019) Yu-Feng Wei et al. Clinical Lung Cancer
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) D Planchard et al. ANNALS OF ONCOLOGY
- Reply to E. Hindié and K.R. Hess
- (2019) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.
- (2019) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).
- (2019) Maria Gonzalez et al. JOURNAL OF CLINICAL ONCOLOGY
- Response of BRAFV600E-Mutant Lung Adenocarcinoma With Brain Metastasis and Leptomeningeal Dissemination to Dabrafenib Plus Trametinib Treatment
- (2019) Gaku Yamamoto et al. Journal of Thoracic Oncology
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
- (2019) Edward B. Garon et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
- (2019) Suzanne L. Topalian et al. JAMA Oncology
- A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor-resistance in melanoma.
- (2019) Y.N. Vashisht Gopal et al. CLINICAL CANCER RESEARCH
- Comparing survival predicted by the diagnosis-specific Graded Prognostic Assessment (DS-GPA) to actual survival in patients with 1–10 brain metastases treated with stereotactic radiosurgery
- (2019) Steven Nagtegaal et al. RADIOTHERAPY AND ONCOLOGY
- 390OEfficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study
- (2019) F Barlesi et al. ANNALS OF ONCOLOGY
- Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort
- (2019) Ariane Steindl et al. JOURNAL OF NEURO-ONCOLOGY
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches
- (2019) Raj Singh et al. RADIOTHERAPY AND ONCOLOGY
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
- (2018) S Novello et al. ANNALS OF ONCOLOGY
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET -Rearranged Lung Cancers
- (2018) Alexander Drilon et al. Journal of Thoracic Oncology
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
- (2018) Georgina V Long et al. LANCET ONCOLOGY
- Intracerebral efficacy and tolerance of nivolumab in non–small-cell lung cancer patients with brain metastases
- (2018) Clément Gauvain et al. LUNG CANCER
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab in Stage III Non–Small-Cell Lung Cancer
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Toward Precision Medicine in Brain Metastases
- (2018) Anna Berghoff et al. SEMINARS IN NEUROLOGY
- Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
- (2018) S Gadgeel et al. ANNALS OF ONCOLOGY
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Thanyanan Reungwetwattana et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
- (2018) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- (2018) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
- (2018) Shirish M. Gadgeel et al. LUNG CANCER
- The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis
- (2017) Fausto Petrelli et al. EUROPEAN JOURNAL OF CANCER
- Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA)
- (2017) Paul W. Sperduto et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
- (2017) Alice Tsang Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases
- (2017) Mengxi Ge et al. JOURNAL OF NEURO-ONCOLOGY
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
- (2017) Michael A Davies et al. LANCET ONCOLOGY
- Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
- (2017) Liang Cheng et al. MODERN PATHOLOGY
- Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)
- (2017) Riccardo Soffietti et al. NEURO-ONCOLOGY
- Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study
- (2017) Daniel N Cagney et al. NEURO-ONCOLOGY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimating Survival in Patients With Lung Cancer and Brain Metastases
- (2017) Paul W. Sperduto et al. JAMA Oncology
- Diagnosis and Treatment of mela-noma Brain Metastasis: A Literature Review
- (2017) Andrew E. Sloan et al. Cancer Control
- Vemurafenib in Metastatic Melanoma Patients with Brain Metastases: An Open-Label, Single-Arm, Phase 2, Multicentre Study
- (2016) GA McArthur et al. ANNALS OF ONCOLOGY
- Systematic review: brain metastases from colorectal cancer—Incidence and patient characteristics
- (2016) Troels Dreier Christensen et al. BMC CANCER
- Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
- (2016) P. Ballard et al. CLINICAL CANCER RESEARCH
- PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo
- (2016) H. Niessner et al. CLINICAL CANCER RESEARCH
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
- (2016) Martin Schuler et al. Journal of Thoracic Oncology
- Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
- (2016) Paula Mulvenna et al. LANCET
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- (2016) Sarah B Goldberg et al. LANCET ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mitochondrial oxidative phosphorylation controls cancer cell’s life and death decisions upon exposure to MAPK inhibitors
- (2016) Paola Corazao-Rozas et al. Oncotarget
- Activity of T-DM1 in Her2-positive breast cancer brain metastases
- (2015) Rupert Bartsch et al. CLINICAL & EXPERIMENTAL METASTASIS
- CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2015) Xavier Pivot et al. JOURNAL OF CLINICAL ONCOLOGY
- Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI
- (2015) Akito Hata et al. Journal of Thoracic Oncology
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
- (2015) P. K. Brastianos et al. Cancer Discovery
- 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
- (2015) Hiroaki Kurihara et al. EJNMMI Research
- Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues
- (2014) Anna Sophie Berghoff et al. ACTA NEUROPATHOLOGICA
- Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
- (2014) S. M. Swain et al. ANNALS OF ONCOLOGY
- Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib
- (2014) L. Peuvrel et al. JOURNAL OF NEURO-ONCOLOGY
- BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib
- (2014) Sara D. Robinson et al. LUNG CANCER
- Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study
- (2014) Aki Morikawa et al. NEURO-ONCOLOGY
- Invasion patterns in brain metastases of solid cancers
- (2013) Anna S. Berghoff et al. NEURO-ONCOLOGY
- Brain metastases free survival differs between breast cancer subtypes
- (2012) A Berghoff et al. BRITISH JOURNAL OF CANCER
- Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
- (2012) Yosuke Togashi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Interim Data from the Medical Research Council QUARTZ Trial: Does Whole Brain Radiotherapy Affect the Survival and Quality of Life of Patients with Brain Metastases from Non-small Cell Lung Cancer?
- (2012) R.E. Langley et al. CLINICAL ONCOLOGY
- Optimal Management of Brain Metastases from Breast Cancer
- (2012) Rupert Bartsch et al. CNS DRUGS
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
- (2012) Thomas Bachelot et al. LANCET ONCOLOGY
- Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
- (2012) Heike Niessner et al. Cancer Medicine
- In Vivo Characterization of Changing Blood-Tumor Barrier Permeability in a Mouse Model of Breast Cancer Metastasis
- (2011) Dean B. Percy et al. INVESTIGATIVE RADIOLOGY
- "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
- (2011) C. Grommes et al. NEURO-ONCOLOGY
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians
- (2011) Wei Zhou et al. Chinese Journal of Cancer
- Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
- (2010) P. R. Lockman et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
- (2010) Kevin C. De Braganca et al. JOURNAL OF NEURO-ONCOLOGY
- High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
- (2010) Jennifer L. Clarke et al. JOURNAL OF NEURO-ONCOLOGY
- Incidence of brain metastases in renal cell carcinoma treated with sorafenib
- (2009) C. Massard et al. ANNALS OF ONCOLOGY
- Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis
- (2009) Jeong-Eun Kim et al. LUNG CANCER
- Real-time imaging reveals the single steps of brain metastasis formation
- (2009) Yvonne Kienast et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now